Corporate GovernanceJun 11, 2026, 04:32 PM
Jade Biosciences Amends Articles to Waive Jury Trials; Updates Bylaws
AI Summary
Jade Biosciences, Inc. held its 2026 Annual Meeting, where stockholders approved an amendment to the Articles of Incorporation to waive jury trials in certain circumstances, effective June 10, 2026. The Board also adopted Amended and Restated Bylaws, effective June 9, 2026, to align with Nevada Revised Statutes, including changes for virtual meetings and updated voting standards. Additionally, stockholders elected two Class II Directors and ratified PricewaterhouseCoopers LLP as the independent auditor for 2026.
Key Highlights
- Stockholders approved an amendment to the Articles of Incorporation to waive jury trials.
- Amended and Restated Articles of Incorporation, including the amendment, were filed on June 10, 2026.
- Board adopted Amended and Restated Bylaws, effective June 9, 2026, for technical and clarifying changes.
- Bylaw amendments allow virtual meetings and update voting standards for stockholder actions.
- Christopher Cain, Ph.D. was elected as a Class II Director with 34,373,784 votes.
- Tom Frohlich was elected as a Class II Director with 42,399,190 votes.
- PricewaterhouseCoopers LLP was ratified as the independent auditor with 46,003,217 votes.
- The jury trial waiver proposal was approved with 39,933,495 votes for.
Price Impact
More from JBIO